



Overall	Events, n	Median, months (95% CI)
Overall (n = 81)	40	12.5 (9.7, 18.3)



Patients at risk:

— 81 75 56 40 27 19 12 8 5 4 1 1 1 1 0


Age	Events, n	Median, months (95% CI)
<75 years (n = 46)	24	11.5 (7.0, 18.3)
≥75 years (n = 35)	16	14.3 (7.3, ne)
<80 years (n = 61)	33	11.5 (9.7, 17.1)
≥80 years (n = 20)	7	ne (5.6, ne)



Patients at risk

— <75 years 46 42 31 21 14 10 9 6 5 4 1 1 1 1 0 0
 — ≥75 years 35 33 25 19 13 9 3 2 0 0 0 0 0 0 0 0
 — <80 years 61 57 44 32 21 14 10 7 5 4 1 1 1 1 0 0
 — ≥80 years 20 18 12 8 6 5 2 1 0 0 0 0 0 0 0 0


Line of therapy	Events, n	Median, months (95% CI)
Treatment-naïve (n = 35)	16	10.9 (7.1, ne)
Previously treated (n = 46)	24	12.7 (9.4, 17.1)



Patients at risk

— Treatment-naïve 35 34 24 16 10 10 8 5 3 2 0 0 0 0 0
 — Previously treated 46 41 32 24 17 9 4 3 2 2 1 1 1 1 0

Prior platinum-based chemotherapy for metastatic disease	Events, n	Median, months (95% CI)
Yes (n = 43)	22	12.7 (9.4, 17.1)



Patients at risk

— Yes 43 39 31 23 17 9 4 3 2 2 1 1 1 1 0 0

Figure S3. Duration of response by investigator assessment. CI, confidence interval; ne, not estimable.